ALX ONCOLOGY HOLDINGS INC — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/51917489-dda8-42a4-8216-61ca3ceca05c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-101.7M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-098454 |
| FY 2024 | $-134.8M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-034761 |
| FY 2023 | $-160.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-027955 |
| FY 2022 | $-123.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007013 |
| FY 2021 | $-83.5M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-007364 |
| FY 2020 | $-45.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-014169 |
| FY 2019 | $-19.2M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-014169 |
| FY 2018 | $-13.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-21-014169 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ALX ONCOLOGY HOLDINGS INC — all facts · Revenue · Operating Income